株探米国株
英語
エドガーで原本を確認する
6-K 1 ea0260778-6k_newgenivf.htm REPORT OF FOREIGN PRIVATE ISSUER

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of October 2025

 

Commission File Number: 001-42004

 

NEWGENIVF GROUP LIMITED

 

36/39-36/40, 13th Floor, PS Tower

Sukhumvit 21 Road (Asoke)

Khlong Toei Nuea Sub-district

Watthana District, Bangkok 10110

Thailand

(Address of Principal Executive Offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

 

Form 20-F ☒         Form 40-F ☐

 

 

 



 

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

 

Interim Results for the Six Months Ended June 30, 2025

 

The unaudited financial results for the six months ended June 30, 2025 (“Interim Results”) of NewGenIvf Group Limited (“NewGen”) and its subsidiaries (collectively, the “Company”) is furnished as Exhibit 99.1 to this report on Form 6-K.

 

Statement Regarding Unaudited Financial Information

 

The unaudited financial information set out in this earnings release is subject to potential adjustments. Adjustments to the consolidated financial statements may be identified when audit work is performed for the Company’s year-end audit, which could result in significant differences from this unaudited financial information.

 

1



 

EXHBIT INDEX

 

Exhibit No.   Description
99.1   NewGenIvf Group Limited’s Unaudited Financial Results for the Six Months Ended June 30, 2025

 

2



 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Date: October 9, 2025

 

  NewGenIvf Group Limited
     
  By: /s/ Wing Fung Alfred Siu
  Name:  Wing Fung Alfred Siu
  Title: Chairman of the Board and Director

 

 

3

 

EX-99.1 2 ea026077801ex99-1_newgenivf.htm NEWGENIVF GROUP LIMITED'S UNAUDITED FINANCIAL RESULTS FOR THE SIX MONTHS ENDED JUNE 30, 2025

Exhibit 99.1

 

NEWGENIVF GROUP LIMITED AND SUBSIDIARIES

 

INDEX TO UNAUDITED CONDENSE CONSOLIDATED FINANCIAL STATEMENTS

 

Unaudited consolidated statements of financial position as of June 30, 2024, and December 31, 2024   F-2
Unaudited consolidated statements of profit or loss and other comprehensive income for the six months ended June 30, 2025 and 2024   F-3
Notes to the unaudited consolidated statements of profit or loss and other comprehensive income   F-4

 

F-1


 

NEWGENIVF GROUP LIMITED

Unaudited consolidated statements of financial position

(Expressed in United States dollars unless otherwise indicated)

 

    June 30,     December 31,  
    2025     2024  
Assets            
Current assets            
Cash and cash equivalents     1,608,475       457,740  
Accounts receivable, net     63,567       49,245  
Inventories     96,094       80,813  
Deposits, prepayments and other receivables, net     2,112,438       1,763,153  
Amount due from related parties     382,687       -  
Amount due from agencies     821,319       821,794  
Total Current Assets     5,084,580       3,172,745  
                 
Other non-current assets                
Plant and equipment, net     348,860       273,096  
Right-of-use assets, net     1,006,397       98,570  
Intangible assets     5,723,683       -  
Investment in Artwork     270,000       -  
Deposits, prepayment and other receivables, net     1,444,346       33,333  
Financial Assets     665,870       -  
Deferred debt issuance cost     274,167       -  
Total non-current assets     9,733,323       404,999  
                 
TOTAL ASSETS     14,817,903       3,577,744  
                 
LIABILITIES AND SHAREHOLDERS’ EQUITY                
Current liabilities                
Accounts payable     876,253       1,298,964  
Accrued liabilities and other payables     344,851       500,729  
Contract liabilities     66,776       63,489  
Due to a related party     -       154,453  
Operating lease liabilities, current     700,774       108,526  
Derivative liability     304,373       -  
Taxes payable     3,738       11,746  
Total current liabilities     2,296,765       2,137,907  
                 
Non—current liabilities                
Operating lease liabilities, non-current     297,980       10,231  
Convertible promissory note     3,434,004       2,911,363  
                 
Total non-current liabilities     3,731,984       2,921,594  
                 
Total liabilities     6,028,749       5,059,501  
                 
Shareholders’ equity                
Ordinary shares, no par value     -       -  
Subscription receivable     -       (204,000 )
Additional paid-in capital     9,577,945       122,505  
Accumulated deficit     (261,019 )     (985,996 )
Accumulated other comprehensive (loss) income     (40,093 )     18,875  
Equity attributable to the shareholders of the Company     9,276,833       (1,048,616 )
Non-controlling interests     (487,679 )     (433,141 )
Total shareholders’ equity     8,789,154       (1,481,757 )
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY     14,817,903       3,577,744  

 

F-2


 

NEWGENIVF GROUP LIMITED

Unaudited consolidated statements of profit or loss and other comprehensive income

(Expressed in United States dollars unless otherwise indicated)

 

    Six Months Ended  
    June 30,
2025
    June 30,
2024
 
             
Revenue     2,019,628       2,686,902  
                 
Cost of revenues     (1,705,824 )     (2,047,970 )
Gross profit     313,804       638,682  
Operating expenses                
Selling and distribution expenses     (307,176 )     (56,732 )
Administrative and other operating expenses     (3,247,004 )     (869,886 )
                 
Total Operating expenses     (3,554,180 )     (926,618 )
                 
Operating (loss)     (3,240,376 )     (287,686 )
                 
Other income (expenses), net                
Other income, net*     4,062,303       7,146  
Interest income     1,594       12,921  
Interest expenses     (125,489 )     (120,162 )
Total other income (expenses), net     3,938,408       (100,095 )
                 
Income (loss) before taxes     698,032       (387,781 )
Provision for income taxes            
Net income (loss)     698,032       (387,781 )
Less: net loss attributable to non-controlling interests     (26,943 )     (8,762 )
Net income (loss) attributable to the shareholders of the Company     724,975       (396,543 )
                 
Other comprehensive income (loss)                
Foreign currency translation adjustment     (66,526 )     270,236  
Total comprehensive income (loss)     631,506       (117,545 )
Less : total comprehensive loss attributable to non-controlling interests     (54,536 )     78,445  
Total comprehensive income attributable to the shareholders of the Company     686,042       (195,990 )
                 
Earning per share – basic **     2.53       (54.14 )
Basic weighted average shares outstanding **     275,936       7,162  

 

* : Please refer to the note at the end of this document
**: Number of share adjusted by reverse stock splits in 2025

 

F-3


 

NEWGENIVF GROUP LIMITED

Notes to the Unaudited consolidated statements of profit or loss and other comprehensive income

(Expressed in United States dollars unless otherwise indicated)

 

OTHER INCOME, NET

 

For the six months ended June 30, 2025, other income, net of US$4,062,303 primarily consisted of the following non-operating items:

 

Purchase Gain on acquiring a business      
Purchase of MicroSort trademarks and other intangible assets     5,284,000  
Less : Consideration Paid        
- Share capital issued at US$2.06 per share, totaling 125,000 shares     (257,500 )
- Settlement in cash paid     (750,000 )
Bargain Purchase Gain     4,276,500  

 

A gain of US$4.3 million was recognized on the acquisition of MicroSort Reproductive Technology. The fair value of the net assets acquired was independently valued at US$5.3 million. The consideration transferred amounted to US$1.0 million, consisting of US$0.75 million in cash and 125,000 ordinary shares valued at US$2.06 per share.

 

Loss on derivates      
Loss on derivates (realized loss of $29,757 and unrealized loss of $304,373)     334,130  

 

A total loss of US$0.3 million was recorded on outstanding derivative contracts related to Nikkei index futures trading, which was engaged as hedging strategy against digital asset exposure.

 

Gain on virtual assets      
Digital asset SOL held on hand     105,680  

 

On December 19, 2024, the Company announced its engagement OSL Digital Securities (“OSL”), a leading regulated digital asset platform in Hong Kong, and its deployment of US$1 million to establish the Company’s digital asset portfolio. On June 2, 2025, the Company announced plans to invest in staking the digital asset SOL (the native token of the Solana network) and funding such investment using its existing credit facilities. As of September 15, 2025, the Company has accumulated total SOL holdings of 13,000.23, valued at approximately US$3.16 million

 

Gain on digital assets A fair value gain of US$0.1 million was recognized on the revaluation of the Company’s holdings of SOL tokens, reflecting fair value adjustment on digital asset holdings.

 

These items are presented net of applicable transaction costs and are integral to understanding the Company’s financial performance during the period.

 

F-4